ASP 4345

Drug Profile

ASP 4345

Alternative Names: ASP-4345

Latest Information Update: 31 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Astellas Pharma
  • Class Antipsychotics; Nootropics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cognition disorders; Schizophrenia

Most Recent Events

  • 22 Mar 2016 Astellas Pharma Global Development plans a phase I trial for Schizophrenia (Adjunctive treatment) in USA (PO) (NCT02720263)
  • 01 Mar 2016 Phase-I clinical trials in Schizophrenia (Adjunctive treatment) in USA (PO) (NCT02720263)
  • 31 May 2015 Phase-I clinical trials in Cognition disorders in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top